Skip to main content

Advertisement

Table 3 Total treatment-emergent adverse events (intent-to-treat population, n = 119)

From: Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Adverse event n (%)
'Flu-like' symptoms 170 (39.4)
Headache 84 (19.4)
Injection-site reaction 46 (10.6)
Gastrointestinal abnormalities 25 (5.8)
Pain 20 (4.6)
Anxiety 13 (3.0)
Infections 10 (2.3)
Hypersensitivity reaction 7 (1.6)
Cytopenia 7 (1.6)
Hepatic disorders 7 (1.6)
Vertigo 6 (1.4)
Upper respiratory tract infection 5 (1.1)
Tachycardia 4 (0.9)
Dysmenorrhoea 3 (0.7)
Other 25 (5.8)
Total 432 (100)